Deka Biosciences, Inc

Dr. Abdul Rafeh Naqash from Stephenson Cancer Center at Oklahoma University will be presenting one of our #SITC2024 posters, titled “Immune Biomarkers from Phase 1 First-in-Human Trial Treating Advanced Cancer Patients with DK2¹⁰(EGFR) compared to ex vivo Diakine™ Response Assay,” sharing key insights from our Phase 1 clinical trial. Thank you, Dr. Naqash, and the brilliant team behind this research: Adanma Ayanambakkam, Alexander Spira, Syed Kazmi, Douglas Orr, Xinhua Zhu, Siqing Fu, Abhishek Tripathi, Aurelien Marabelle, David Langan, Alice Hsu, Jacob McCright, Steven Dudics, Fatima Hamdan, Benjamin George, Phillip Kuri, Allison Long, Deb Kientop, Stanley Frankel, and John Mumm. #CancerResearch #Biotech #Immunotherapy #DekaBiosciences

We're proud to share our latest research at #SITC2024 with two different posters. One of them, titled "Balanced Diakine™ targeted cytokines localize within the immunological synapse and augment immune response in combination with T cell engagers," will be presented by Dr. Jacob McCright from Deka. A huge thank you to Jacob and the incredible team behind this work: Steven Dudics, Alice Hsu, David Langan, Benjamin George, Phillip Kuri, Antony Haider, Karen Huang, Fatima Hamdan, Javier Goitia, Julie Ahn, Christopher Yaen, Stanley Frankel, and John Mumm. Together, we’re advancing the field of immunotherapy by exploring new ways to strengthen immune responses and develop more effective treatments for patients. #Biotech #Cytokines #CancerResearch #DekaBiosciences

Our CEO, Dr. John Mumm, presented at the SAPA-DC 2024 Annual Conference this past weekend, delivering an insightful presentation titled "Paradigm Shift for Therapeutic Use of Cytokines." Grateful to have been a part of such an inspiring event, where thought leaders are driving meaningful change in biotech. Thank you, SAPA-DC, for having us! #Biotech #Cytokines #Innovation #Leadership #SAPA_DC #DekaBiosciences

We are excited to share that Deka, along with our partners, will be presenting two posters at SITC 2024! Will we see you there? #SITC24

We are thrilled to welcome Dr. Jacques Banchereau to Deka’s Scientific Advisory Board! Dr. Banchereau, a globally recognized leader in immunology, brings over four decades of experience in both academic and industry settings. His groundbreaking contributions to our understanding of cytokines, inflammation, and systems immunology have significantly advanced the field. With a focus on the discovery and characterization of human cytokines and the biology of B-cells and dendritic cells, Dr. Banchereau has made significant strides in vaccine development and immune therapies. His expertise in areas such as cancer and autoimmune diseases will be a tremendous asset to Deka as we continue to innovate and drive forward cutting-edge solutions in healthcare and science. We're excited to have Dr. Banchereau on board and look forward to his valuable contributions. Join us in welcoming Dr. Banchereau to the team!

We are thrilled to share that Deka will be presenting at this week’s Immuno-Oncology Summit in Philadelphia! If you’re attending, we invite you to join us for the following sessions:   Tumor Microenvironment Track: “Detoxifying and Improving IL-2 Potency through Combination with IL-10 and Targeting to the TME,” presented by John Mumm, PhD.   Emerging Tech for IO Targeting and Discovery Track: “Ramifications of Tethering T Cell-Activating Cytokines to the Surface of Tumor Cells,” presented by Jacob McCright, PhD.   We look forward to connecting with you and sharing our latest research advancements. #IOSummit #immunooncology #cancerresearch #drugdevelopment

It was an honor to present our poster at ASCO this weekend, sharing the initial results from our Phase 1 clinical trial of DK2¹⁰ (EGFR). A heartfelt thank you to our many partners and collaborators who have made this possible, including: Dr. Alexander I. Spira, Dr. Siqing Fu, Dr. Abdul Rafeh Naqash, Dr. Adanma Ayanambakkam, Dr. Syed Mohammad Ali Kazmi, Dr. Abhishek Tripathi, Dr. Aurelien Marabelle, Dr. Xinhua Zhu, and Dr. Douglas W. Orr. Your support and dedication have been instrumental in our progress. #ASCO2024 #ClinicalResearch #ClinicalTrial #Oncology

Our Scientist, Jacob McCright, presenting on day 2 of Cytokine-Based Drug Development Summit. What a wonderful way to end this insightful summit! #cytokinedrugdevelopment

Our CBO, Pavel Khrimian, chairing on day 2 of Cytokine-based Drug Development Summit. #Cytokines #Cytokinedrugdevelopment

Deb Kientop, our VP of Clinical Operations, speaking today at the 5th Annual Cytokine Based Drug Development Summit. #Cytokinedrugdevelopment